Authors
Angelos Hatzakis, Suzanne Wait, J Bruix, Miquel Buti, M Carballo, M Cavaleri, Massimo Colombo, E Delarocque‐Astagneau, G Dusheiko, G Esmat, Rafael Esteban, D Goldberg, C Gore, Anna Suk-Fong Lok, M Manns, P Marcellin, G Papatheodoridis, A Peterle, D Prati, N Piorkowsky, Mario Rizzetto, F Roudot‐Thoraval, Virtudes Soriano, HC Thomas, M Thursz, D Valla, P Van Damme, IK Veldhuijzen, Heiner Wedemeyer, L Wiessing, AR Zanetti, HLA Janssen
Publication date
2011/9
Journal
Journal of viral hepatitis
Volume
18
Pages
1-16
Publisher
Blackwell Publishing Ltd
Description
Worldwide, the hepatitis B virus (HBV) and the hepatitis C virus (HCV) cause, respectively, 600 000 and 350 000 deaths each year. Viral hepatitis is the leading cause of cirrhosis and liver cancer, which in turn ranks as the third cause of cancer death worldwide. Within the WHO European region, approximately 14 million people are chronically infected with HBV, and nine million people are chronically infected with HCV. Lack of reliable epidemiological data on HBV and HCV is one of the biggest hurdles to advancing policy. Risk groups such as migrants and injecting drug users (IDU) tend to be under‐represented in existing prevalence studies; thus, targeted surveillance is urgently needed to correctly estimate the burden of HBV and HCV. The most effective means of prevention against HBV is vaccination, and most European Union (EU) countries have universal vaccination programmes. For both HBV and HCV …
Total citations
Scholar articles
A Hatzakis, S Wait, J Bruix, M Buti, M Carballo… - Journal of viral hepatitis, 2011